GlycoFi Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GlycoFi Inc.
Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care
Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.
Believing In Biosimilars: Industry Takes Long View on FDA Pathway
FDA is open for business on biosimilars as it works out the specifics of the new review pathway. But for companies considering an entry into the space, two big questions still remain: Does a profitable market exist, and how conservative will FDA be on those initial approvals? Executives from across the biopharmaceutical industry weigh in during The RPM Report’s FDA/CMS Summit.
The Allure Of High-Hanging Fruit: Why VCs and Biotech Execs See Value In Difficult Drug Targets
An agile and energetic cohort of biotech platform companies plans to capture Big Pharma's imagination--and its pocketbook--by going after intractable drug targets that have long eluded the industry, and they're doing it on a shoestring budget.
Opening A Door To Biosimilars In The US
With the regulatory door ajar, companies across the pharmaceutical industry are vying to dominate the biosimilars space, despite the commercial risks.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals